<DOC>
	<DOCNO>NCT00463723</DOCNO>
	<brief_summary>Background : Patients follow allogeneic keratoplasty treat topical frequently systemic steroid prevent immune reaction . Steroids known yield good result , exert wide range side effect . The efficacy topial FK506 prevent immune reaction already demonstrate experimentally . FK506 , IL-2-inhibitor like Cyclosporin A ( CSA ) , know approximately 100 fold potent CSA . Aim study : In study efficacy safety topical FK506 compare standard treatment ( i.e . steroid ) penetrate normal-risk keratoplasty .</brief_summary>
	<brief_title>Topical FK506 ( Tacrolimus ) Prevention Immune Reactions Following Penetrating Keratoplasty</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Penetrating keratoplasty Keratoconus Penetrating keratoplasty Fuchs endothelial dystrophie Penetrating keratoplasty Bullous keratopathy Glaucoma Limbal stem cell deficiency Herpetic eye disease Repeat Keratoplasty</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1999</verification_date>
	<keyword>penetrate keratoplasty</keyword>
	<keyword>graft rejection</keyword>
	<keyword>immunosuppression</keyword>
</DOC>